Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab.
Zecchetto C, Quinzii A, Casalino S, Gaule M, Pesoni C, Merz V, Pietrobono S, Mangiameli D, Pasquato M, Milleri S, Giacopuzzi S, Bencivenga M, Tomezzoli A, de Manzoni G, Melisi D. Zecchetto C, et al. Among authors: pietrobono s. J Pers Med. 2023 Mar 11;13(3):508. doi: 10.3390/jpm13030508. J Pers Med. 2023. PMID: 36983691 Free PMC article.
SOX2 as a novel contributor of oxidative metabolism in melanoma cells.
Andreucci E, Pietrobono S, Peppicelli S, Ruzzolini J, Bianchini F, Biagioni A, Stecca B, Calorini L. Andreucci E, et al. Among authors: pietrobono s. Cell Commun Signal. 2018 Nov 22;16(1):87. doi: 10.1186/s12964-018-0297-z. Cell Commun Signal. 2018. PMID: 30466459 Free PMC article.
Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S, Gaudio E, Gagliardi S, Zitani M, Carrassa L, Migliorini F, Petricci E, Manetti F, Makukhin N, Bond AG, Paradise BD, Ciulli A, Fernandez-Zapico ME, Bertoni F, Stecca B. Pietrobono S, et al. Oncogene. 2021 Jun;40(22):3799-3814. doi: 10.1038/s41388-021-01783-9. Epub 2021 May 6. Oncogene. 2021. PMID: 33958721 Free PMC article.
29 results